BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

NCT03749187 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma
IDH1 Gene Mutation
IDH2 Gene Mutation
Low Grade Glioma
Malignant Glioma
Recurrent Glioblastoma
Recurrent WHO Grade II Glioma
Recurrent WHO Grade III Glioma
WHO Grade II Glioma
WHO Grade III Glioma

Interventions

DRUG: PARP Inhibitor BGB-290
DRUG: Temozolomide (TMZ)

Sponsor

University of California, San Francisco

Collaborators

[object Object]